Acute Lymphoblastic Leukemia Archives - Cancer Therapy Advisor

Preparing patients for treatment toxicity is important for ensuring that mild or moderate reactions

Hematologic Cancers

Calaspargase and Pegaspargase Produce Comparable Results in Newly Diagnosed Acute Lymphoblastic Leukemia

By

Sucharita Mistry, PhD

July 29, 2021

Efficacy and toxicity outcomes were similar with calaspargase and pegaspargase.

Hematologic Cancers

Rylaze Approved For Patients Allergic to E. coli-Derived Asparaginase Products

By

Brian Park, PharmD

July 6, 2021

Rylaze will be supplied as single-dose vials containing 10mg/0.5mL solution of asparaginase erwinia chrysanthemi (recombinant)-rywn and is expected to be available in mid-July 2021.

Hematologic Cancers

Transcranial Direct Current Stimulation in Adult Survivors of Pediatric Acute Lymphoblastic Leukemia

By

Cancer Therapy Advisor Staff

June 18, 2021

The primary outcome of the study is to evaluate the efficacy of home-based tDCS combined with remote cognitive training on direct testing of executive function in survivors of ALL.

Hematologic Cancers

Phase 3 Trial Evaluates Inotuzumab Ozogamicin Plus Frontline Chemotherapy in B-Cell ALL

By

Cancer Therapy Advisor Staff

June 18, 2021

Investigators seek to evaluate how the addition of inotuzumab ozogamicin to frontline chemotherapy affects patients with newly diagnosed B-cell ALL.

Hematologic Cancers

Reducing Maintenance Produced ‘Outstanding’ Survival Outcomes in Pediatric Acute Lymphoblastic Leukemia

By

Sucharita Mistry, PhD

June 17, 2021

Survival rates were similar whether maintenance was given every 12 weeks or every 4 weeks.

An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting.

ASCO 2021

Model May Identify Non-ETP T-ALL Patients at High Risk of Poor Response to Treatment

By

Leah Lawrence

June 7, 2021

The model appears to predict minimal residual disease status.

Median overall survival was 42 months in patients who received sorafenib and 13 months in patients who received chemotherapy alone.

Hematologic Cancers

Acute Lymphoblastic Leukemia Patients With Half-Matched Donors See Improved Outcomes

By

Christina Bennett, MS

May 13, 2021

Outcomes have improved during the past decade for patients with acute lymphoblastic leukemia who undergo haploidentical hematopoietic cell transplantation.

A 10% reduction in calorie intake during the first month of treatment shows promise for augmenting chemotherapy treatment in children and adolescents with ALL.

Hematologic Cancers

Caloric Reduction Improves Outcomes for Young People With Acute Lymphoblastic Leukemia

By

Victoria Forster, PhD

May 10, 2021

A 10% reduction in calorie intake during the first month of treatment shows promise for augmenting chemotherapy treatment in children and adolescents with ALL.

Patients with anemia had worse in-hospital outcomes.

Hematologic Cancers

Risk Factors Found for Requiring Glucarpidase

By

Leah Lawrence

April 26, 2021

Researchers have identified certain novel risk factors for requiring glucarpidase rescue associated with high-dose methotrexate, including Hispanic ethnicity.

Nilotinib in combination with chemotherapy is highly effective in Philadelphia chromosome-, BCR-ALB1

Hematologic Cancers

Short-Term 6-TG Exposure During Treatment for Pediatric ALL Associated With Hepatic SOS

By

Colby Stong

April 23, 2021

Investigators analyzed the association between hepatic SOS and short-term application of 6-TG in 3983 pediatric ALL patients.